You are here

  • Home
  • Archive
  • Volume 32, Issue Suppl 2
  • 2022-RA-1492-ESGO Homologous recombination deficiency (HRD): a new ovarian cancer biomarker – validation of decentralized genomic profiling, with a focus on genomic large rearrangements (LRs)

Citation Tools

Article menu

Download PDFPDF

Ovarian cancer
2022-RA-1492-ESGO Homologous recombination deficiency (HRD): a new ovarian cancer biomarker – validation of decentralized genomic profiling, with a focus on genomic large rearrangements (LRs)
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Denkert C, Romey M, Swedlund B, et al
2022-RA-1492-ESGO Homologous recombination deficiency (HRD): a new ovarian cancer biomarker – validation of decentralized genomic profiling, with a focus on genomic large rearrangements (LRs)
International Journal of Gynecologic Cancer 2022;32:A343.